PMID- 34675680
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Circular RNA Circ-0003006 Promotes Hepatocellular Carcinoma Proliferation and 
      Metastasis Through Sponging miR-542-3p and Regulating HIF-1A.
PG  - 7859-7870
LID - 10.2147/CMAR.S315894 [doi]
AB  - INTRODUCTION: Hepatocellular carcinoma (HCC) is one most common cancer types 
      among gastrointestinal cancer over the world, while its underlying mechanisms 
      remain unclear. CircRNA has been revealed to participate in multiple biological 
      functions and contribute to various diseases' progression. METHODS: Bioinformatic 
      analysis of the differently expressed circRNAs in the HCC tissues, then verified 
      by real-time quantitative PCR (RT-qPCR) assay. We found that circ-0003006 was 
      upregulated in the HCC tissues, the cell fractionation assay and RNA fluorescence 
      in situ hybridization (FISH) were performed to confirm the cell location of 
      circ-0003006. shRNA silence assay was used to knock down the expression of 
      circ-0003006 in the HCC cells. RESULTS: Cell account kit 8 (CCK-8) and transwell 
      assay were revealed that circ-0003006 knockdown inhibited the proliferation and 
      metastasis in HCC cells. The target miR‑542‑3p and target gene HIF-1A were 
      predicted by bioinformatics analysis, then verified through biotinylated RNA 
      pull-down and dual-luciferase reporter assays. The mechanism, circ-0003006, 
      probably acted as a sponge of miR‑542‑3p and regulated HIF-1A levels in 
      hepatocellular carcinoma cells. Moreover, HIF-1A overexpression abolished the 
      effect of circ-0003006 inhibition on the progression of hepatocellular carcinoma 
      cells. The subcutaneous tumor formation experiment indicated that circ-0003006 
      knockdown inhibited the HCC cell growth in vivo. CONCLUSION: Circ-0003006 was 
      demonstrated to promote HCC progression in vitro and in vivo by sponging 
      miR‑542‑3p to release the inhibition on HIF-1A.
CI  - (c) 2021 Tu et al.
FAU - Tu, Qiang
AU  - Tu Q
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
FAU - You, Xiaoxiang
AU  - You X
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
FAU - He, Jun
AU  - He J
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
FAU - Hu, Xuguang
AU  - Hu X
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
FAU - Xie, Changji
AU  - Xie C
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
FAU - Xu, Guohui
AU  - Xu G
AD  - Department of Hepatobiliary Oncology Surgery, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
AD  - Department of Oncology Interventional, Jiangxi Cancer Hospital of Nanchang 
      University, Nanchang, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20211013
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8520847
OTO - NOTNLM
OT  - HIF-1A
OT  - circ-0003006
OT  - circular RNA
OT  - hepatocellular carcinoma
OT  - miR-542-3p
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/23 06:00
MHDA- 2021/10/23 06:01
PMCR- 2021/10/13
CRDT- 2021/10/22 06:46
PHST- 2021/05/13 00:00 [received]
PHST- 2021/09/30 00:00 [accepted]
PHST- 2021/10/22 06:46 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/23 06:01 [medline]
PHST- 2021/10/13 00:00 [pmc-release]
AID - 315894 [pii]
AID - 10.2147/CMAR.S315894 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Oct 13;13:7859-7870. doi: 10.2147/CMAR.S315894. 
      eCollection 2021.